DiaMedica Therapeutics (DMAC) investor relations material

Key product and clinical development updates

• Developing a synthetic recombinant form of KLK1 protein for preeclampsia and acute ischemic stroke, targeting unmet medical needs with a protein replacement therapy approach.

• Proof of concept data showed the drug lowers blood pressure and increases placental blood flow, with a strong safety profile and no placental crossing.

• Phase II trial for preeclampsia launching soon in North America, with ongoing trials in South Africa and multiple clinical readouts expected through next year.

• Pivotal trial for acute ischemic stroke underway, with interim analysis on first 200 patients expected by year-end and potential completion the following quarter.

• Drug targets root causes by increasing vasodilatory factors, improving endothelial health, and is modeled after successful crude protein forms used in Asia.

Market opportunity and financial position

• Addressable market for both preeclampsia and stroke estimated at $7–15 billion each.

• $60 million in cash provides runway through 2027, with no warrants or debt.

• Clinical strategy leverages extensive Asian data on crude protein forms to guide patient targeting and trial design.

• Five analysts currently cover the company, including Cantor, TD Cowen, H.C. Wainwright, Lake Street, and Craig-Hallum.

Mechanism of action and physician feedback

• Drug increases blood flow by activating bradykinin B2 receptors, releasing nitric oxide, prostacyclin, and EDHF, which are depressed in target patients.

• For preeclampsia, aims to extend gestation by improving placental blood flow and controlling blood pressure without fetal exposure.

• For stroke, increases collateral circulation in ischemic brain regions, potentially improving recovery rates.

• Physicians show high interest, especially in preeclampsia, due to lack of current treatment options and favorable safety profile.